NEW YORK (GenomeWeb News) - Ingenuity Systems today said that AstraZeneca has signed a global licensing agreement for its IPA pathway analysis platform.
 
Adriano Henney, director of discovery enabling capabilities and sciences at AstraZeneca, said in a statement that the company opted for IPA after testing several platforms across seven AstraZeneca sites in three countries for the past year.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.